Skip to main content
    X

    Xencor Inc (XNCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.00
    +0.61 (+2.61%)

    Market Cap: $1.74B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    +93.96%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.40
    Range$-1.21 - $0.22
    12 analysts
    EPS Revisions
    5
    0
    7d
    5
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.82+51.7%
    60d ago$-0.83+52.4%
    30d ago$-0.32-22.9%
    7d ago$-0.400.0%
    Current$-0.40
    Revenue Consensus
    $59M
    Range$3M - $115M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.17
    Range$-2.48 - $0.12
    12 analysts
    Revenue Consensus
    $39M
    Range$-42693020 - $95M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.17---
    Sep 26EST
    		-$-0.40---
    Jun 26
    Reported Aug 5
    		$-0.29N/A+64.63%Beat+29.3%
    Mar 26
    Reported May 6
    		$-1.71$-0.75-128.00%Miss-159.1%
    Dec 25
    Reported Feb 25
    		$-0.09N/A+85.09%Beat+85.5%
    Sep 25
    Reported Nov 5
    		$-0.08N/A+88.89%Beat+88.7%
    Jun 25
    Reported Aug 6
    		$-0.41$-0.71+42.25%Beat+61.7%
    Mar 25
    Reported May 7
    		$-0.66$-0.58-13.79%Miss+40.5%
    Dec 24
    Reported Feb 27
    		$-0.62$-0.79+21.14%Beat-100.0%
    Sep 24
    Reported Nov 6
    		$-0.71$-1.02+30.39%Beat-77.5%
    Jun 24
    Reported Aug 5
    		$-1.07$-0.79-35.44%Miss-189.2%
    Mar 24
    Reported May 9
    		$-1.11$-0.77-44.16%Miss-8.8%
    Dec 23
    Reported Feb 27
    		$-0.31$-0.09-244.44%Miss-55.0%
    Sep 23
    Reported Nov 7
    		$-0.40$-0.71+43.66%Beat+27.3%
    Jun 23
    Reported Aug 3
    		$-0.37N/A+54.32%Beat+35.1%
    Mar 23
    Reported May 8
    		$-1.02$-0.66-54.55%Miss-361.5%
    Dec 22
    Reported Feb 23
    		$-0.20N/A+75.31%Beat-116.5%
    Sep 22
    Reported Nov 7
    		$-0.55$-0.72+23.61%Beat+20.3%
    Jun 22
    Reported Aug 3
    		$-0.57$-0.47-21.28%Miss-165.5%
    Mar 22
    Reported May 5
    		$0.39$-0.45+186.67%Beat+1075.0%
    Dec 21
    Reported Feb 23
    		$1.21$-0.10+1310.00%Beat+604.2%
    Sep 21
    Reported Nov 8
    		$-0.69$-0.70+1.43%Beat-213.6%
    Jun 21
    Reported Aug 4
    		$0.87$-0.55+258.18%Beat+242.6%
    Mar 21
    Reported May 5
    		$-0.04N/A+94.03%Beat+71.4%
    Dec 20
    Reported Feb 23
    		$-0.24$-0.46+47.83%Beat+48.9%
    Sep 20
    Reported Nov 5
    		$-0.22$-0.22+0.00%Beat-22.2%
    Jun 20
    Reported Aug 4
    		$-0.61$-0.50-22.00%Miss-117.9%
    Mar 20
    Reported May 7
    		$-0.14N/A+65.85%Beat-110.1%
    Dec 19
    Reported Feb 24
    		$-0.47$-0.41-14.63%Miss-46.9%
    Sep 19
    Reported Nov 5
    		$-0.18N/A+66.04%Beat-460.0%
    Jun 19
    Reported Aug 6
    		$-0.28$-0.45+37.78%Beat+39.1%
    Mar 19
    Reported May 9
    		$1.38$0.09+1433.33%Beat+322.6%
    Dec 18
    Reported Feb 25
    		$-0.32$-0.49+34.69%Beat-28.0%
    Sep 18
    Reported Nov 5
    		$0.05N/A+109.62%Beat+115.2%
    Jun 18
    Reported Aug 6
    		$-0.46$-0.57+19.30%Beat-206.7%
    Mar 18
    Reported May 7
    		$-0.62$-0.47-31.91%Miss-100.0%
    Dec 17
    Reported Feb 27
    		$-0.25$-0.35+28.57%Beat-19.0%
    Sep 17
    Reported Nov 7
    		$-0.33$-0.31-6.45%Miss-
    Jun 17
    Reported Aug 7
    		$-0.15$-0.23+34.78%Beat-
    Mar 17
    Reported May 9
    		$-0.31$-0.28-10.71%Miss-
    Dec 16
    Reported Feb 28
    		$-0.21$-0.32+34.38%Beat-

    Key Metrics

    Valuation
    P/E Ratio-11.06EV/EBITDAN/A
    Price/FCF-8.74xFCF Yield-11.44%
    Profitability
    Profit Margin-155.60%Operating Margin-72.40%
    ROE-29.10%ROIC-25.78%
    Financial Health
    Debt/Equity0.21xInterest Coverage-5.79x
    Current Ratio6.39xQuick Ratio6.39x
    Trading Statistics
    Beta0.90Avg Volume1.50M
    52-Week High$30.6152-Week Low$10.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.42
    SMA 20$24.57
    SMA 50$24.97
    SMA 200$16.28
    EMA 10$24.26
    EMA 20$24.49
    EMA 50$23.68
    EMA 200$18.03

    MACD

    Line: -0.17Signal: -0.02Hist: -0.15

    ADX

    ADX: 17.8+DI: 16.3-DI: 23.8

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down80.0
    PSAR$25.23

    Bollinger Bands

    Upper Band$25.83
    Lower Band$23.31
    %B Position1027%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    46.6

    Momentum Oscillators

    Stoch %K28.4
    Stoch %D38.1
    Williams %R-62.0
    ROC (10d)-3.1%
    Momentum-0.77
    CCI (20d)-108.4
    MFI (14d)50.1

    Volatility Measures

    ATR (14d)$1.30(5.4%)
    StdDev (20d)0.63
    Hist Vol46.6%(High)

    Volume Flow

    VWAP$23.81
    OBV18.0M
    AD Line-3.1M
    CMF (20d)-0.048

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.5x(Low)
    VWMA (20d)$24.57

    Pivot Points

    R3$25.07
    R2$24.67
    R1$24.03
    Pivot Point$23.62
    S1$22.98
    S2$22.58
    S3$21.94

    Advanced Oscillators

    TSI-4.42
    Ultimate Osc49.8
    KST-36.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51.22M$4.52M$28.24M$21.00M$43.61M$32.73M$52.79M$17.80M$23.91M$16.00M$50.97M$59.16M
    Cost of Revenue$0$0$2.58M$0$0$0$51.06M$0$0$0$3.23M$0
    Gross Profit$51.22M$4.52M$28.24M$21.00M$43.61M$32.73M$52.79M$17.80M$23.91M$16.00M$50.97M$59.16M
    Operating Expenses$88.29M$82.38M$81.86M$68.52M$76.78M$75.92M$65.97M$72.99M$79.28M$70.66M$78.32M$77.43M
    R&D$71.91M$64.67M$64.82M$54.37M$61.66M$58.58M$51.06M$58.23M$61.53M$56.87M$63.05M$64.94M
    SG&A$16.38M$17.71M$17.04M$14.15M$15.12M$17.34M$14.91M$14.77M$17.75M$13.79M$15.27M$12.49M
    Operating Income$-37,068,000$-77,862,000$-53,628,000$-47,519,000$-33,172,000$-43,183,000$-13,178,000$-55,197,000$-55,370,000$-54,663,000$-27,351,000$-18,270,000
    Interest Income$4.80M$5.46M$6.20M$6.54M$7.25M$7.54M$8.16M$7.54M$7.68M$8.55M$7.64M$5.02M
    Interest Expense$7.35M$4.70M$7.35M$7.67M$8.24M$8.66M$8.66M$9.03M$9.28M$9.68M$6.16M$7,000
    Income Before Tax$-21,919,000$-128,636,000$-4,266,000$-6,027,000$-31,075,000$-48,265,000$-44,583,000$-47,442,000$-68,782,000$-74,116,000$-12,648,000$-24,269,000
    Income Tax Expense$-190,000$280,000$2.39M$0$-250,000$367,000$1.62M$0$0$0$0$0
    Net Income$-21,729,000$-128,916,000$-6,653,000$-6,027,000$-30,825,000$-48,632,000$-46,200,000$-47,442,000$-68,782,000$-74,116,000$-26,310,000$-24,269,000
    EBITDA$-16,934,000$-126,956,000$-875,000$-3,963,000$-26,790,000$-46,571,000$-40,503,000$-47,792,000$-68,988,000$-76,864,000$-16,326,000$-30,011,000
    EBIT$-19,367,000$-129,395,000$-3,112,000$-4,900,000$-30,080,000$-47,138,000$-44,088,000$-45,953,000$-67,181,000$-72,988,000$-14,130,000$-29,285,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XNCR

    News

    Truist raises target for Xencor stock to USD 29

    Truist Securities increased its price target for Xencor (XNCR) stock to USD 29 from USD 27, maintaining a Buy rating. This adjustment is based on the anticipated clinical update for XmAb819 at the European Society...

    ad-hoc-news.de•10/15/26•Bullish

    Xencor, Inc. (XNCR) Stock Forecasts

    Argus provided a quantitative report on Xencor Inc. (XNCR) on October 14, 2026, summarizing the company as a clinical-stage biopharmaceutical firm developing engineered antibody therapeutics for cancer and autoimmune...

    Yahoo Finance•10/14/26•Somewhat-Bullish

    Understanding Momentum Shifts in (XNCR)

    This article provides an analysis of Xencor Inc. (NASDAQ: XNCR), highlighting a potential shift from weak near-term sentiment to long-term strength. It details specific trading strategies, including position...

    Stock Traders Daily•10/14/26•Bullish

    Xencor, Inc. (XNCR) Stock Forecasts

    Xencor Inc. (XNCR) had its rating decreased to "SELL" by Argus on September 30, 2026. The biopharmaceutical company, which focuses on engineered antibody therapeutics for cancer and autoimmune diseases...

    Yahoo! Finance Canada•10/14/26•Bearish

    Xencor, Inc. (XNCR) Stock forecasts

    Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical company focused on developing engineered antibody therapeutics. Argus lowered its target price for XNCR to $19.00 on October 7, 2026...

    Yahoo Finance UK•10/9/26•Somewhat-Bearish

    XNCR Valuation and Fair Value

    P/E
    -11.1x
    Forward P/E
    68.0x
    P/FCF
    -8.7x
    PEG
    0.0x
    P/B
    3.6x
    See GNG's fair value

    XNCR Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -72.4%
    Net margin
    -155.6%
    ROIC
    -25.8%
    ROE
    -29.1%
    FCF margin
    -198.4%
    FCF yield
    -11.4%

    XNCR Competitors

    CompanyTicker
    Vir Biotechnology IncVIR
    Sonida Senior Living IncSNDA
    Palvella Therapeutics, IncPVLA
    Alignment Healthcare LLCALHC
    Sarepta Therapeutics IncSRPT
    Trevi Therapeutics IncTRVI
    Xeris Pharmaceuticals IncXERS
    Personalis IncPSNL

    Sector: Healthcare

    XNCR Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    3
    Buy
    9
    Hold
    2
    Sell
    0
    Strong Sell
    0

    XNCR Bull Case vs Bear Case

    Bull case

    • XNCR beat EPS estimates in 75.0% of its last 8 reported quarters.
    • XNCR grew quarterly revenue 17.5% year over year.
    • 85.7% of XNCR's analyst ratings are Buy or Strong Buy.

    Bear case

    • XNCR has a -155.6% net profit margin.

    XNCR Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    23.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.40
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    5 up, 0 down

    Frequently Asked Questions About XNCR

    Does XNCR pay dividends?

    Xencor Inc (XNCR) does not currently pay a regular dividend.

    What is XNCR's market cap?

    Xencor Inc (XNCR) has a market capitalization of $1.74B with a current stock price of $24.00.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In